Navco Pharmaceuticals Inc.
NAV.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.56% | 44.00% | 95.52% | 93.75% | 95.72% |
| Total Depreciation and Amortization | -- | -- | 100.00% | -100.00% | -97.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.41% | 35.71% | -99.67% | 100.79% | -99.48% |
| Change in Net Operating Assets | -147.37% | -85.71% | -70.98% | -100.86% | 108.23% |
| Cash from Operations | -358.62% | -128.57% | 85.79% | 50.81% | 92.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -9.09% | -- | -100.00% | -100.00% | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.88% | -- | -100.00% | -100.00% | 525.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.13% | 62.79% | 3.57% | -21.33% | 128.77% |